Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Selinexor |
XPO1 (Exportin-1) Inhibitor | Hematologic (Multiple Myeloma/DLBCL) | ||
|
Molecule
Selinexor
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma/DLBCL)
Drug Class / Mechanism
XPO1 (Exportin-1) Inhibitor |
||||
Selpercatinib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Selpercatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Selumetinib |
BRAF / MEK Inhibitor | Solid Tumour | ||
|
Molecule
Selumetinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
||||
Semaxanib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Semaxanib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Senaparib |
PARP Inhibitor | Solid Tumour | ||
|
Molecule
Senaparib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
||||
Serabelisib |
PI3K Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Serabelisib
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
||||
Serplulimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Serplulimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
SHR6390 (Dalpiciclib) |
CDK Inhibitor | Solid Tumour | ||
|
Molecule
SHR6390 (Dalpiciclib)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
||||
Simmiparib |
PARP Inhibitor | Solid Tumour | ||
|
Molecule
Simmiparib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
||||
Sintilimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Sintilimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Sipuleucel-T |
Autologous Cellular Immunotherapy | Solid Tumour (Prostate) | ||
|
Molecule
Sipuleucel-T
Therapeutic Category
Cellular Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Autologous Cellular Immunotherapy |
||||
Siremadlin |
MDM2 Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Siremadlin
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
||||
SelinexorTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma/DLBCL)
Drug Class / Mechanism
XPO1 (Exportin-1) Inhibitor |
|
SelpercatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
SelumetinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
BRAF / MEK Inhibitor |
|
SemaxanibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
SenaparibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
|
SerabelisibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
PI3K Inhibitor |
|
SerplulimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
SHR6390 (Dalpiciclib)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
CDK Inhibitor |
|
SimmiparibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
PARP Inhibitor |
|
SintilimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
Sipuleucel-TCellular Therapy |
|
|
Therapeutic Category
Cellular Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Autologous Cellular Immunotherapy |
|
SiremadlinTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
|